AI and the Future of Work: Artificial Intelligence in the Workplace, Business, Ethics, HR, and IT for AI Enthusiasts, Leaders and Academics
Host Dan Turchin, PeopleReign CEO, explores how AI is changing the workplace. He interviews thought leaders and technologists from industry and academia who share their experiences and insights about artificial intelligence and what it means to be human in the era of AI-driven automation. Learn more about PeopleReign, the system of intelligence for IT and HR employee service: http://www.peoplereign.io.
AI and the Future of Work: Artificial Intelligence in the Workplace, Business, Ethics, HR, and IT for AI Enthusiasts, Leaders and Academics
290: Adityo Prakash, Founder & CEO of Verseon, On Extending Life With AI
Adityo Prakash is a serial entrepreneur, high-tech CEO, amateur photographer, and author who transitioned from academia to revolutionize video streaming, and is now transforming drug discovery and commercialization. As the founder of Verseon, Adityo employs deep quantum modeling and AI to expedite the identification and development of innovative pharmaceuticals, potentially reshaping our approach to aging and healthcare. With degrees in math and physics from Caltech and over 40 patents to his name, Adityo is at the forefront of technological advancements in the medical field.
In this conversation, we discuss:
- How Verseon uses deep quantum modeling and AI to revolutionize drug discovery and development, aiming to change the standard of care for various diseases.
- Adityo's journey from Caltech, where he studied math and physics, to founding Verseon and securing over 40 patents.
- The challenges and opportunities at the intersection of high tech and biotech, and how these fields are converging to create new platform companies.
- The limitations of traditional trial-and-error drug discovery methods and how Verseon's approach offers a more systematic, atom-by-atom design of new drugs.
- The potential for AI and advanced modeling techniques to address complex health issues like aging, by treating it as a disease with identifiable therapeutic targets.
- The future of drug development, regulatory challenges, and how the integration of AI and physics could transform the pharmaceutical industry over the next decade.
Resources
An episode you might like about which AI businesses are getting investor dollars
